175 related articles for article (PubMed ID: 23815529)
21. Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.
Tin A; Grams ME; Maruthur NM; Astor BC; Couper D; Mosley TH; Fornage M; Parekh RS; Coresh J; Kao WH
Clin J Am Soc Nephrol; 2015 May; 10(5):784-90. PubMed ID: 25887069
[TBL] [Abstract][Full Text] [Related]
22. APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy.
Robinson TW; Freedman BI
Kidney Int; 2017 Feb; 91(2):276-278. PubMed ID: 28087008
[TBL] [Abstract][Full Text] [Related]
23. Coding variants in nephrin (NPHS1) and susceptibility to nephropathy in African Americans.
Bonomo JA; Ng MC; Palmer ND; Keaton JM; Larsen CP; Hicks PJ; ; Langefeld CD; Freedman BI; Bowden DW
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1434-40. PubMed ID: 24948143
[TBL] [Abstract][Full Text] [Related]
24. Genetics. Kidney disease is parasite-slaying protein's downside.
Leslie M
Science; 2010 Jul; 329(5989):263. PubMed ID: 20647431
[No Abstract] [Full Text] [Related]
25. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.
Atta MG; Estrella MM; Kuperman M; Foy MC; Fine DM; Racusen LC; Lucas GM; Nelson GW; Warner AC; Winkler CA; Kopp JB
Kidney Int; 2012 Aug; 82(3):338-43. PubMed ID: 22495294
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.
Nadkarni GN; Galarneau G; Ellis SB; Nadukuru R; Zhang J; Scott SA; Schurmann C; Li R; Rasmussen-Torvik LJ; Kho AN; Hayes MG; Pacheco JA; Manolio TA; Chisholm RL; Roden DM; Denny JC; Kenny EE; Bottinger EP
J Am Coll Cardiol; 2017 Mar; 69(12):1564-1574. PubMed ID: 28335839
[TBL] [Abstract][Full Text] [Related]
27. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.
Tzur S; Rosset S; Skorecki K; Wasser WG
Nephrol Dial Transplant; 2012 Apr; 27(4):1498-505. PubMed ID: 22357707
[TBL] [Abstract][Full Text] [Related]
28. APOL1 and nephropathy progression in populations of African ancestry.
Freedman BI
Semin Nephrol; 2013 Sep; 33(5):425-32. PubMed ID: 24119848
[TBL] [Abstract][Full Text] [Related]
29. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
[TBL] [Abstract][Full Text] [Related]
30. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in APOL1 associates with younger age at hemodialysis initiation.
Kanji Z; Powe CE; Wenger JB; Huang C; Ankers E; Sullivan DA; Collerone G; Powe NR; Tonelli M; Bhan I; Bernhardy AJ; Dibartolo S; Friedman D; Genovese G; Pollak MR; Thadhani R
J Am Soc Nephrol; 2011 Nov; 22(11):2091-7. PubMed ID: 21997398
[TBL] [Abstract][Full Text] [Related]
32. Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD.
Palmer ND; Ng MC; Langefeld CD; Divers J; Lea JP; Okusa MD; Kimberly RP; Bowden DW; Freedman BI
J Am Soc Nephrol; 2015 May; 26(5):1021-5. PubMed ID: 25249559
[TBL] [Abstract][Full Text] [Related]
33. Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?
Wasser WG; Kruzel-Davila E
Clin J Am Soc Nephrol; 2015 May; 10(5):723-5. PubMed ID: 25887068
[No Abstract] [Full Text] [Related]
34. Apolipoprotein L1 and Kidney Disease in African Americans.
Friedman DJ; Pollak MR
Trends Endocrinol Metab; 2016 Apr; 27(4):204-215. PubMed ID: 26947522
[TBL] [Abstract][Full Text] [Related]
35. Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors.
Riella LV; Sheridan AM
Am J Kidney Dis; 2015 Sep; 66(3):396-401. PubMed ID: 26049628
[TBL] [Abstract][Full Text] [Related]
36. African American living-kidney donors should be screened for APOL1 risk alleles.
Cohen DM; Mittalhenkle A; Scott DL; Young CJ; Norman DJ
Transplantation; 2011 Oct; 92(7):722-5. PubMed ID: 21878839
[TBL] [Abstract][Full Text] [Related]
37. Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.
Ku E; Lipkowitz MS; Appel LJ; Parsa A; Gassman J; Glidden DV; Smogorzewski M; Hsu CY
Kidney Int; 2017 Feb; 91(2):443-450. PubMed ID: 27927600
[TBL] [Abstract][Full Text] [Related]
38. APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults.
Mukamal KJ; Tremaglio J; Friedman DJ; Ix JH; Kuller LH; Tracy RP; Pollak MR
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):398-403. PubMed ID: 26634651
[TBL] [Abstract][Full Text] [Related]
39. The AJT Report: news and issues that affect organ and tissue transplantation. Genetic factor may limitkidney donation.
Pondrom S
Am J Transplant; 2012 Nov; 12(11):2865-6. PubMed ID: 23107266
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.
Freedman BI; Langefeld CD; Murea M; Ma L; Otvos JD; Turner J; Antinozzi PA; Divers J; Hicks PJ; Bowden DW; Rocco MV; Parks JS
Nephrol Dial Transplant; 2011 Nov; 26(11):3805-10. PubMed ID: 21931123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
